INVA vs RAPP
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
INVA · Innoviva$18.41 ▲ 0.00%
RAPP · Rapport Therapeutics$23.16 ▼ 1.82%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- INVA -13.5%
- RAPP -18.2%
Head to head
| Metric | INVA | RAPP |
|---|---|---|
| Price | $18.41 | $23.16 |
| Change today | ▲ 0.00% | ▼ 1.82% |
| Market cap | $1.31B | $1.37B |
| Return, 3 months | -12.5% | -53.1% |
| Return, year to date | -7.9% | -23.7% |
| Return, 1 year | -12.2% | -15.0% |
| P/E (TTM) | 7.8 | – |
| P/B | 1.2 | 3.5 |
| P/E percentile vs own 5y | 61st | 73rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -1.6% | – |
| Net profit growth (YoY) | -182.2% | -49.4% |
| Gross margin | 80.5% | – |
| Operating margin | 38.8% | -838.1% |
| Net margin | 44.1% | -752.4% |
| Return on equity | 18.0% | -33.3% |
| Analyst target vs. price | +106.4% | +193.6% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 29 | 37 |
| 30-day volatility | 34.7% | 99.9% |
| Max drawdown, 1 year | -24.5% | -57.1% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RAPP is the largest of the group by market value.
- INVA has returned the most over the past year.
- INVA keeps the most profit per dollar of sales.
- INVA has been the calmest stock over the last 30 days.